Summary
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.
The global Human Rabies Immunoglobulin (IM) market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
ERIG
HRIG
Demand Coverage (Market Size & Forecast, Consumer Distribution):
Category II Exposure
Category III Exposure
Company Coverage (Sales data, Main Products & Services etc.):
CSL Behring
Grifols 
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS
Major Region Market
North America
Europe
Asia-Pacific
South America
Middle East & Africa

Table of Content
1 Industry Overview
1.1 Human Rabies Immunoglobulin (IM) Industry
1.1.1 Overview
1.1.2 Products of Major Companies
1.2 Market Segment
1.2.1 Industry Chain
1.2.2 Consumer Distribution
1.3 Price & Cost Overview
2 Human Rabies Immunoglobulin (IM) Market by Type
2.1 By Type
2.1.1 ERIG
2.1.2 HRIG
2.2 Market Size by Type
2.3 Market Forecast by Type
3 Global Market Demand
3.1 Segment Overview
3.1.1 Category II Exposure
3.1.2 Category III Exposure
3.2 Market Size by Demand
3.3 Market Forecast by Demand
4 Major Region Market
4.1 Global Market Overview
4.1.1 Market Size & Growth
4.1.2 Market Forecast
4.2 Major Region
4.2.1 Market Size & Growth
4.2.2 Market Forecast
5 Major Companies List
5.1 CSL Behring (Company Profile, Sales Data etc.)
5.2 Grifols  (Company Profile, Sales Data etc.)
5.3 Sanofi (Company Profile, Sales Data etc.)
5.4 Sichuan Yuanda Shuyang (Company Profile, Sales Data etc.)
5.5 CNBG (Company Profile, Sales Data etc.)
5.6 Kamada (Company Profile, Sales Data etc.)
5.7 CBPO (Company Profile, Sales Data etc.)
5.8 Shuanglin Bio (Company Profile, Sales Data etc.)
5.9 Weiguang Bio (Company Profile, Sales Data etc.)
5.10 Shanghai RAAS (Company Profile, Sales Data etc.)
5.11 Bharat Serum (Company Profile, Sales Data etc.)
5.12 VINS (Company Profile, Sales Data etc.)
6 Conclusion